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Abstract
Purpose: The question of whether mesenchymal stromal cells (MSCs) home to injured kidneys
remains a contested issue. To try and understand the basis for contradictory findings reported in
the literature, our purpose here was to investigate whether MSC homing capacity is influenced
by administration route, the type of injury model used, and/or the presence of exogenous
macrophages.
Procedures: To assess the viability, whole-body biodistribution, and intra-renal biodistribution of
MSCs, we used a multimodal imaging strategy comprising bioluminescence and magnetic
resonance imaging. The effect of administration route (venous or arterial) on the ability of MSCs
to home to injured renal tissue, and persist there, was assessed in a glomerular injury model
(induced by the nephrotoxicant, Adriamycin) and a tubular injury model induced by ischaemia-
reperfusion injury (IRI). Exogenous macrophages were used as a positive control because these
cells are known to home to injured mouse kidneys. To assess whether the homing capacity of
MSCs can be influenced by the presence of exogenous macrophages, we used a dual-
bioluminescence strategy that allowed the whole-body biodistribution of the two cell types to be
monitored simultaneously in individual animals.
Results: Following intravenous administration, no MSCs were detected in the kidneys,
irrespective of whether the mice had been subjected to renal injury. After arterial administration
via the left cardiac ventricle, MSCs transiently populated the kidneys, but no preferential homing
or persistence was observed in injured renal tissue after unilateral IRI. An exception was when
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MSCs were co-administered with exogenous macrophages; here, we observed some homing of
MSCs to the injured kidney.
Conclusions: Our findings strongly suggest that MSCs do not home to injured kidneys.
Key Words: Bioluminescence, Magnetic resonance, Kidney disease, MSCs, Macrophages,
Stromal cells, Cell tracking, Luciferase
Introduction
Numerous studies have shown that mesenchymal stromal
cells (MSCs) from various sources, including bone marrow,
adipose tissue and the umbilical cord, can improve renal
function and ameliorate tissue damage following adminis-
tration into rodents with kidney injury [1]. However, the
mechanisms are ill-defined and it is not clear if the MSCs
engraft in injured kidneys or not. Some studies have
presented data that suggest MSCs home to injured kidneys,
and that renal engraftment is necessary for their therapeutic
effects [2, 3], whereas others suggest that MSCs do not
engraft and that any therapeutic benefit is likely due to
paracrine or endocrine factors [4, 5]. If the former scenario
were correct, it would be expected that MSCs administered
intravenously (IV) might be less effective in rodent kidney
injury models than MSCs administered intra-arterially (i.e.,
via the renal artery, carotid artery, descending aorta or left
cardiac ventricle). This is because, following IV administra-
tion, most cells become trapped in the lungs due to the
pulmonary first-pass effect [6–8], whereas intra-arterial
administration delivers more cells to the kidneys [9]. In
support of this, a meta-analysis has indicated that the intra-
arterial route gives greater benefit in rodents than the IV
route [10]. However, biodistribution studies present contra-
dictory findings, with some showing that even after injecting
MSCs into the renal artery, they are mainly localised to the
lung [11], whereas others show that in animals with renal
injury, cells administered arterially are mostly localised in
the kidney [12]. These discrepancies could result from a
variety of reasons; for instance, different methods being used
to induce renal impairment; MSCs being administered at
different time points following injury; different tracking
methods being used to determine the location of the MSCs.
Cell tracking methods that rely solely on identifying MSCs
on histological sections using fluorescence microscopy can
be particularly problematic due to the fact that the kidney
emits intense autofluorescence, which can be increased even
further following renal injury [13].
To obtain more accurate information about MSC
biodistribution in vivo and ascertain how this might be
affected by the route of administration, we have previously
applied a bi-modal imaging approach comprising biolumi-
nescence imaging (BLI) and magnetic resonance imaging
(MRI) to respectively monitor the whole-body and intra-
renal biodistribution of mouse MSCs in mice [9]. This was
achieved by introducing the firefly luciferase (FLuc) reporter
into the MSCs to permit BLI following administration of the
substrate, luciferin, and by labelling the MSCs with
superparamagnetic iron oxide nanoparticles (SPIONs) so
that they could be identified using MRI. In addition to
facilitating whole-body imaging, an advantage of FLuc-BLI
is that it is an indicator of living cells. A key advantage of
MRI is that the spatial resolution is much higher than with
BLI, so that it is possible to determine the position of
SPION-labelled cells within the kidney [14]. By applying
this bi-modal strategy to healthy mice, we found that MSCs
administered IV remained trapped in the lungs, but those
injected into the left cardiac ventricle could populate the
kidneys. Irrespective of administration route, however, most
primary MSC types, including human bone marrow-derived
MSCs, did not persist in any organ beyond 48 h.
In the current study, using two different mouse injury
models where the site of injury is primarily the glomeruli
(adriamycin model) or the proximal tubules (ischaemia-
reperfusion injury (IRI) model), we have applied this bi-
modal imaging strategy to determine if mouse MSCs home
to injured kidneys following systemic administration, and
whether they persist there. As a positive control cell
population, we have used the RAW 264.7 mouse macro-
phage line which had been reported to ameliorate renal
injury in mice [5] and can home to injured tissues [15].
Finally, given that some studies suggest that the therapeutic
effects of MSCs are mediated by macrophages [5, 16], we
have used a dual-bioluminescence imaging strategy recently
developed in our lab that comprises FLuc and a NanoLuc
(NLuc)-based bioluminescence resonance energy transfer
(BRET) reporter [17], to investigate whether the
biodistribution of FLuc+ macrophages is affected by co-
administration of NLuc+ MSCs, and vice-versa.
Methods
Cell Labelling
The mouse mesenchymal stem/stromal cell (MSC) D1 line
was obtained from the American Type Culture Collection
(CRL-12424) and RAW 264.7 mouse macrophages were
obtained from the European Collection of Authenticated Cell
Cultures (#91062702). Both cell types were originally
derived from BALB/c mice [18, 19]. Cells were transduced
with a lentiviral vectors encoding a bicistronic construct of
Firefly Luciferase (FLuc) and ZsGreen under control of the
constitutive promoter EF1α or a previously described
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bioluminescence resonance energy transfer (BRET) reporter
[17], also under the control of EF1α. The production and
titration of viral particles was performed using established
protocols [20]. The cells were transduced with a multiplicity
of infection of 5 in the presence of polybrene (8 μg/ml) for
the MSCs and without polybrene for the RAW macro-
phages. At least 90 % of the MSCs expressed the transgenes
after transduction whereas macrophages, due to the poor
transduction efficiency, were sorted based on ZsGreen
fluorescence using an Aria fluorescence-activated cell sorter
(BD Biosciences). Both cell lines were maintained in
Dulbecco’s Modified Eagle’s medium with 10 % foetal calf
serum at 37 °C in a humidified incubator with 5 % CO2.
Iron oxide labelling for MR detection was carried out by
co-incubation of the cells with the particles for a period of
24 h prior to administration to mice, after which cells were
washed and harvested for injection. Cationic SPIONs
produced in-house [21, 22] were used for labelling the
MSCs (labelling concentration: 25 μg[Fe]/ml; iron content
after labelling: ~ 5 pg[Fe]/cell) whereas macrophages were
labelled with ferumoxytol (AMAG pharmaceuticals, label-
ling concentration: 20 μg[Fe]/ml, iron content after labelling:
~ 6.5 pg[Fe]/cell). The use of different SPIONs is required
because each cell type responds differently to such materials,
e.g., ferumoxytol alone does not effectively label MSCs
[23], but do label RAW macrophages without affecting their
morphology or viability [24]. In all experiments, cells were
trypsinised, pelleted, resuspended in ice-cold phosphate
buffered saline (PBS) and kept on ice until injection. The
cell suspension (100 μl) was administered to mice intrave-
nously via the tail vein or intracardially (IC) via the left
ventricle of the heart via ultrasound guidance (Prospect
system, S-Sharp, Taiwan) [9].
Models of Kidney Injury
BALB/c mice (Charles River, UK) were housed in individ-
ually ventilated cages under a 12-h light/dark cycle, with ad
libitum access to standard food and water. All animal
experiments were performed under a licence granted under
the UK Animals (Scientific Procedures) Act 1986 and were
approved by the University of Liverpool ethics committee.
ARRIVE guidelines were followed to report animal exper-
iments. This mouse strain is expected to accept the two cell
lines used in this study, irrespective of animal’s immune
status.
Adriamycin nephropathy was induced in female BALB/c
SCID mice by injecting adriamycin (ADR, doxorubicin
hydrochloride, Tocris, UK) IV at 6.3 mg/kg body weight
(BW) in 0.9 % saline. Cells were administered 14 days post
ADR, when renal impairment is observed [25]. For IRI,
male mice were anaesthetised with isoflurane and a flank
incision was made for unilateral clamping of the renal
pedicle for 40 min, using an atraumatic vascular clamp.
Subsequently, the vascular clamp was removed and
restoration of renal blood flow confirmed visually prior to
repair of muscle and skin layers. In this model, renal
impairment is observed 24 h post-clamping [26] and cells
were administered at this time point.
Imaging
For bioluminescence imaging, a subcutaneous injection of
luciferin (150 mg/kg body weight, Promega, UK) was
administered to mice under anaesthesia, which were imaged
15 min later in a bioluminescence imager (IVIS Spectrum,
Perkin Elmer, UK). Imaging data were normalised to the
acquisition conditions and expressed as radiance (photons/s/
cm2/sr (p/s/cm2/sr)). For ex vivo BLI, mice were culled
10 min post administration of luciferin, after which organs
were harvested and immediately imaged. Bioluminescence
signals of whole animals or individual organs ex vivo were
quantified by drawing regions of interest (ROIs) from which
the total flux (photons/second) was obtained. For simulta-
neous tracking of MSCs and RAWs in the same animal,
MSCs were transduced with a BRET reporter and imaged
in vivo and ex vivo as previously reported [17]. In brief, the
imaging protocol involves the tail vein cannulation of the
mice, injection of the substrates (furimazine or luciferin) IV
and sequential acquisition of data. The BRET signal from
the MSCs is obtained immediately after furimazine injection
and because the half-life of this substrate is very short, the
signal is cleared within approximately 10 min. This allows
subsequent injection of luciferin and collection of Fluc
signal from the RAW macrophages in the same imaging
session, without crosstalk between the different reporter
systems. Ex vivo imaging involves a similar method, but the
firefly luciferase signal is collected before the BRET signal
[17].
MR data was obtained with a Bruker Avance III console
interfaced to a 9.4 T magnet system (Bruker Biospec 94/20
USR) and a 4-channel receive-only abdominal surface coil in
combination with a 72-mm resonator. Mice were imaged at
baseline (before injury) and at multiple time points post
administration of SPION-labelled cells. A gated Fast Low-
Angle Shot (FLASH) T2* sequence was used with the
following acquisition parameters: TE 5.5 ms, TR 262.5 ms,
flip angle 20 °, matrix size 386 × 386 pixels, field of view
35 × 35 mm, slice thickness 0.5 mm, number of slices 20,
averages 3, acquisition time 5 min, 35 s. T2
* relaxation times
were obtained from a T2
* map by drawing ROIs around the
cortex of the kidney or a region of the liver as previously
described [9]. The T2
* maps were obtained with a
multigradient echo (MGE) sequence with 8 echoes starting at
4.5 ms with 4.5 ms increments and TR 900 ms, flip angle 50 °,
matrix size 256 × 256 pixels, field of view 35 × 35 mm, slice
thickness 0.5 mm, number of slices 20, averages 2, acquisition
time 5 min, 45 s. For postmortem imaging of kidneys, the
organs were fixed in formaldehyde, embedded in agarose and
imaged with a FLASH T2
* sequence with following
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acquisition parameters: TE 6.3 ms, TR 1300 ms, flip angle
20 °, matrix size 400 × 400 pixels, field of view 17 × 17 mm,
slice thickness 0.2 mm, number of slices 70, averages 24,
acquisition time 3 h, 20 min.
Results
A Combination of MRI and BLI Allows the in vivo
Imaging of MSC Delivery to the Kidneys, but Does
Not Provide Evidence of Preferential Persistence
or Homing to the Injured Kidney
We applied an imaging protocol involving the double
labelling of MSCs with SPIONs and FLuc to allow their
imaging via MRI and BLI, respectively. In MRI, the SPION
label creates local magnetic field inhomogeneities in the
areas where cells are delivered to, leading to decay of
transverse magnetisation, which is observed as hypointense
(dark) contrast in T2
*-weighted imaging. This is usually used
to image a specific organ or body region. BLI, on the other
hand allows assessment of the whole-body distribution of
cells. SPION+FLuc+ MSCs were administered into the left
cardiac ventricle of mice with adriamycin-induced injury or
IRI. Irrespective of the injury model, MR imaging performed
within a few hours of cell administration showed
hypointense contrast in the renal cortices (Fig. 1a). This
confirmed that administration via the arterial route leads to
successful delivery of the cells to the kidneys. Hypointense
contrast was additionally observed in the medulla of kidneys
following IRI (Fig. 1a, blue arrows); however, this phenom-
enon was also observed in the absence of administered cells
(see Fig. 1 in Electronic Supplementary Material (ESM)),
suggesting a surgery-specific effect. The contrast in the renal
cortices was progressively lost in the subsequent days,
indicating that the cells were cleared from the kidneys.
Quantification of the T2
* relaxation time, the time constant
that describes the decay of transverse magnetisation,
revealed a statistically significant reduction on the adminis-
tration day but recovery to baseline values in the following
days (Fig. 1b, c). For mice that underwent IRI, we compared
the relaxation times of injured kidney with that of the
uninjured contralateral kidney but saw no differences
between the two (see Fig. 2a in ESM). In the liver of IRI
mice, the T2
* relaxation time dropped progressively through-
out the experimental period to values that were significantly
different from baseline by days 1 and 2, whereas the T2
*
relaxation time was significantly lower than baseline on all
days after cell administration in the ADR model (Fig. 1b, c).
This suggests that SPIONs are transported from the kidneys
to the liver in the days subsequent to cell administration. BLI
revealed whole-body distribution of MSCs on the adminis-
tration day, as anticipated from injection via the arterial
route. A progressive loss of signal intensity was seen in the
days following cell administration, suggesting cell death. By
day 2, only a weak signal was detected in the kidneys, which
is consistent with the loss of MR contrast. Taken together,
these data suggest loss of MSCs from the kidneys via
progressive cell death, following which, the SPION label is
transported to the liver, most likely by the host’s reticulo-
endothelial system.
Similarly to MSCs, RAW Macrophages Are Short-
Lived in the Kidneys but Populate the Liver
Having observed no persistence of MSCs in the kidneys, we
investigated whether macrophages have a different fate. From
here, our study focuses on the unilateral IRI model given the
presence of an internal control kidney in each animal. A total of
5 × 106 cells were administered, based on a dose-finding study
that showed that these cells are well tolerated when injected via
the left ventricle of the heart [9]. MR imaging revealed a similar
renal distribution as observed with the MSCs, with strong
negative contrast in the cortex on the administration day and
progressive loss on the following days (Fig. 2a). Indeed, the
changes in T2
* relaxation times in the renal cortices and liver
follow the same behaviour as we observed for the MSCs (Fig.
2b), and as before, no differences were seen when comparing
the injured kidney with the control kidney (see Fig. 2b in
ESM). However, when animals were analysed individually, we
noticed that some appeared to display a greater negative
contrast in the injured kidney on the administration day (see
Fig. 3 in ESM). BLI imaging displayed a different distribution
to that seen with the MSCs, with a moderate loss of signal on
day 1, but an increase in signal in the spine and liver by day 2
suggesting that the cells had populated these organs (Fig. 2c).
This implies that for this cell type, the reduction in T2
*
relaxation time in the liver was probably a combination of two
components: (i) SPION debris from RAW macrophages that
have died after administration and (ii) viable SPION+ FLuc+
RAW macrophages that home to the liver. The differences in
cell fate between the two cell types are also evident when mice
are imaged ventrally (see Fig. 4 in ESM), with a marked signal
originating from the liver of mice that receive macrophages but
not from those that receive MSCs.
To confirm the MR data obtained in vivo, we scanned the
kidneys postmortem at a higher resolution. Ex vivo imaging of
the kidneys of mice that received MSCs exhibited the same
features as observed in vivo: (i) hypointense contrast in the renal
cortex on day 0, which was lost in subsequent days; (ii) nomajor
differences between the distribution of cells in the cortex of
healthy and injured kidneys; and (iii) a darkening of the medulla
of the injured kidney (Fig. 3). Imaging of the kidneys of animals
that received macrophages displayed a similar pattern, but the
contrast in the cortex was stronger which is likely a consequence
of the higher injection dose (5 × 106 RAWs vs 106 MSCs),
meaning that more cells are present in the kidneys on the
administration day. Interestingly, a careful examination of the
images revealed that more hypointense spots were present in the
injured kidney, particularly on day 1, when compared with the
healthy kidney (Fig. 3, red arrows). Taken together, the in vivo
and ex vivo MR imaging of macrophages suggest a greater
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accumulation or persistence of cells in the injured kidney, but
this could not be unambiguously demonstrated in a quantitative
manner using this imaging modality.
BLI ex vivo Provides Improved Sensitivity and
Reveals Distinct Behaviour Between Macrophages
and MSCs
To quantitatively determine whether macrophages do prefer-
entially persist in the injured kidney as suggested by the MR
data, mice were culled 24 h post cell administration for ex vivo
imaging of the organs via bioluminescence. Imaging of the
lungs, liver, spleen, heart and kidneys revealed that cells were
present in all major organs at this time point with lungs and
liver displaying the strongest signal intensity (Fig. 4). Analysis
of the signal intensity in each of the kidneys showed an
increase in the mean signal in the injured kidneys when mice
received the MSCs IC, but this was not statistically significant
(p = 0.16, Fig. 4a). Mice that received the macrophages IC, on
the other hand, displayed a statistically significant difference
Fig. 1. In vivo MR/BL imaging provides evidence of MSC delivery to the kidneys, but no clear differences in the presence of a
kidney injury. a MRI of the kidneys at baseline (prior to injury) and up to 2 days post intracardiac administration of 106 cells to
SCID mice with an adriamycin or ischaemia-reperfusion renal injury. On the cell administration day (day 0), hypointense
contrast was seen in the cortices of the kidneys (red arrows), indicating cell delivery. The contrast is lost in subsequent days. In
the IRI model, hypointense contrast is also seen in the medulla of the injured kidney (blue arrows). b T2
* relaxation time of the
kidneys’ cortices and liver in the ADR model. c T2
* relaxation time of the kidneys and liver in the IRI model. Time points that do
not share the same letters are significantly different from one another, p G 0.05 (Tukey’s post hoc test). p values for all
comparisons are shown in SI Table 1. d BLI on cell administration day (day 0) shows whole-body distribution of cells, including
the kidneys but the signal is progressively lost in subsequent days, suggesting cell death
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between kidneys, with the injured having a greater biolumi-
nescence intensity (p = 0.032, Fig. 4b). Because it is known
that RAWmacrophages are able to bypass the lung vasculature
when administered IV [9], we assessed whether this route of
administration can also lead to cells accumulating preferen-
tially in the injured kidney. Administration of 107 cells via this
route confirmed their ability to extravasate the lungs, with cells
also populating the liver, spleen and kidneys (Fig. 4c). A
Fig. 2. In vivo MR/BL imaging provides evidence of macrophage delivery to the kidneys, but no clear differences between
injured (left) and healthy (right) kidney. a MRI of the kidneys at baseline and up to 2 days post administration of 5 × 106 cells to
SCID mice with an ischemia/reperfusion injury. On the cell administration day (day 0), hypointense contrast is seen in the
cortices of the kidneys, indicating cell delivery. The contrast is lost in subsequent days. b T2
* relaxation time of the kidney
cortices and livers. Time points that do not share the same letters are significantly different from one another, p G 0.05 (Tukey’s
post hoc test). p values for all comparisons are shown in SI Table 2. c BLI on cell administration day (day 0) shows whole-body
distribution of cells, including the kidneys but the signal changes progressively in subsequent days, and by day 2, the signal is
predominately found in the liver (dashed area) and spine
Fig. 3. Ex vivo high-resolution MRI supports the findings observed in vivo (Figs. 1 and 2). On day 1, more hypointense areas
appear to be present in the injured kidneys of SCID mice that underwent IRI and received macrophages (red arrows)
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stronger bioluminescence intensity was detected in the injured
kidneys (p = G 0.001) suggesting a homing effect where these
cells actively migrate to the site of ischaemic injury. Of note,
our experimental setup only allowed us to detect those
differences when imaging the organs ex vivo. Our attempts to
quantify the signal emanating from the kidneys in vivo were
unsuccessful due to the presence of cells in other organs, the
surgical scar overlying the injured kidney and the low spatial
resolution of BLI (ESM Fig. 5).
Multiplex Imaging Allows the Tracking of each
Cell Independently and Suggests no Crosstalk
Between RAW Macrophages and MSCs
Having determined differences in the homing and persis-
tence of MSCs and RAW macrophages in mice with IRI, we
next sought to identify whether the biodistribution of the
MSCs could be influenced by the presence of exogenous
macrophages. For this, we co-injected MSCs and RAW
macrophages into the same mice and applied a method to
track them individually, using a combination of NanoLuc-
based BRET reporter and FLuc. Shortly following IC
administration, both cell types showed a similar whole-
body distribution, with good co-localisation of the MSC and
macrophage signal on day 0 (Fig. 5a). On day 1, the signal
weakened, in agreement with the data in Figs. 1 and 2, with
some MSCs still present in the abdominal area, including the
kidneys and brain, whereas the macrophage signal was most
intense in the spine. A different scenario emerged when the
cells were administered IV, with both types of cells being
found exclusively in the lungs on the day of administration.
A strong reduction in signal intensity was observed by day
1, with MSCs still located in the lungs, whereas macro-
phages were found not only in the lungs, but also in the
abdomen.
Ex vivo imaging of organs on day 1 showed similar
results to those obtained when the cells were administered
individually. After IC administration, MSCs were found in
most organs including the kidneys, with a stronger signal
intensity in the injured kidney (Fig. 5b). In contrast to the
data shown in Fig. 4a, we saw a statistically significant
difference between the kidneys in this experimental setup.
We have previously shown that MSCs expressing this BRET
reporter have a light output much greater than that of cells
expressing FLuc [17] and it is thus possible that these results
reflect a greater sensitivity of the reporter, allowing us to
detect a statistically significant difference which was not
observed with FLuc. However, it is also possible that the
increased numbers of RAW macrophages in the injured
kidney may restrict blood flow through the glomerular
capillaries, causing a transient accumulation of MSCs.
Following IV administration, no MSCs were detected in
any organ apart from the lungs (Fig. 5b). RAW macro-
phages, on the other hand, produced a stronger signal in the
injured kidney that was statistically significant irrespective
of the administration route, demonstrating that their homing
is not affected by co-administration of MSCs.
Discussion
MSCs are efficacious in various preclinical models of renal
injury [10], but whether their therapeutic effects are
dependent on their ability to populate the kidneys is a
contested issue; for instance, some reports have suggested
that efficacy is improved with enhanced renal homing of
MSCs [2], while others suggest that improvements in renal
health occur in the absence of homing [4, 5]. To determine
whether MSCs home to injured kidneys or not, we used
Fig. 4. Ex vivo BLI is more sensitive and suggests prefer-
ential survival or retention of cells in the injured kidney of
mice that underwent IRI. a 106 MSCs administered IC, b 5 ×
106 RAWs administered IC, and c 107 RAWs administered IV.
Left: Representative BLI of individual organs on day 1 post
cell administration. Organs from the same animal were
imaged at the same time and under the same acquisition
conditions. Lu, lungs; Li, liver; S, spleen; H, heart; K, healthy
kidney; Ki, injured kidney. Right: Quantification of the total
flux from each of the kidneys. MSC IC, n = 6; RAW IC, n = 3;
RAW IV, n = 6
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multimodal imaging to assess MSC biodistribution follow-
ing IV and IC administration in two different mouse models
of renal injury. In contrast to macrophages, which served as
a positive control, we found little evidence of any MSC renal
homing capacity.
We have previously shown that stem cell administration
via the intracardiac route prevents the well-known pulmo-
nary first-pass effect, allowing cells to reach the kidneys [9].
However, in this previous study only healthy mice were
used. Here, we sought to assess whether the presence of a
glomerular (Adriamycin) or tubular (IRI) injury affects the
persistence and survival of the cells in this organ. In the
former model, both kidneys are injured, requiring compar-
ison with a control group. Comparison with our previous
data, which involved the same mouse strain, same MSC line
and the same labelling/imaging strategy [9] reveals that
survival and persistence are not affected by renal injury, with
the great majority of the cells dying or being cleared from
the kidneys in the days subsequent to their administration.
When compared with the ADR model, the unilateral
Fig. 5. Simultaneous in vivo tracking of MSCs and RAW macrophages co-administered to SCID mice that underwent IRI. a BLI
signal as obtained from MSCs (BRET reporter) or macrophages (Fluc) without any colour scaling, and an overlay with pseudo-
colours (red: MSCs, green: macrophages). The same images, displayed with a “rainbow” scale for each of the conditions, are
shown in the Fig. 6 in ESM. b, c Representative images of organs imaged ex vivo on day 1 post administration (b, MSCs; c,
RAWs). d Quantification of the total flux from each of the ex vivo kidneys. IC administration n = 6, IV administration n = 7
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ischemia/reperfusion model provides the advantage of an
internal control within the same animal. The behaviour of
the cells in the IRI model was similar to that observed with
healthy or adriamycin-injured animals; that is, an initial
accumulation was observed in the renal cortices followed by
cell death and/or rapid clearance. A similar dynamic was
observed when injecting macrophages. It is important to note
that the ADR is a model of glomerular injury, while IRI
predominantly damages the proximal tubules. Nevertheless,
MRI signal after IC administration was seen predominantly
in the cortices, but not in the renal tubules, irrespective of
the injury model. We have previously shown that when
administered IC, cells that reach the kidney are found
predominantly in the glomeruli [25], which are highly
vascularised. These observations indicate that although the
IC route results in good delivery of MSCs to the kidneys,
their distribution in this organ likely relates to vascular
entrapment rather than to active homing to the site of injury.
Bioluminescence imaging the organs ex vivo offers
greater sensitivity because there is much less signal
attenuation in the absence of surrounding tissue. On the first
day following macrophage administration, a difference in the
signal intensity between the injured and control kidney in
the IRI model was observed, which has two important
implications.
The first concerns the sensitivity of the technologies
used here. The combination of MRI and BLI in vivo
provided important information to whether cells reached
the kidneys as well as their intra-renal distribution and
long-term survival, but was not sufficiently robust to
allow us to detect subtle differences in signal between
the two kidneys. Although in the case of macrophages,
qualitative differences were seen between the kidneys of
individual animals via MRI in vivo, these were not
reflected when the mean relaxation time of whole groups
was compared. This shows the need to confirm in vivo
data postmortem.
The second implication concerns the biological response
of administered cells to the renal injury. Administration of
MSC and RAWs via the IC route led to a stronger BLI
signal in the injured kidneys on day 1, implying the presence
of a greater number of cells. We have not yet established the
specific mechanisms on which the stronger signals in the
injured kidneys are based, but important questions arise: Are
the administered cells attracted to the site of injury due to
local chemokine release? Is the phenomenon based on
physical entrapment due to underlying changes in the
structure of the kidney as a result of the ischaemic injury?
The observation that IV injected macrophages also produce
a stronger signal in the injured kidney suggests that at least
for this cell type, chemoattraction likely takes place. Indeed,
it is well recognized that chemokine-mediated infiltration of
macrophages takes place in ischaemic acute kidney injury
[27]. This has additional implications when their action as a
cell therapy is taken into consideration, as it suggests that
both the venous and arterial routes are effective in delivering
macrophages to the site of injury. Importantly, the same has
not been seen with MSCs. Although previous studies have
suggested that MSCs bypass the lungs and reach the kidneys
after IV administration, most of those studies used imaging
methods that are prone to false positives, e.g., (i) the use of
lipophilic dyes [28] that can be transferred to host cells [29]
or (ii) reliance on histological sections, which can give false
positive results due to the increased levels of autofluores-
cence in injured kidneys [13, 29].
Our imaging with reporter genes that are specific to
viable cells provides clear, unambiguous evidence that IV
administered MSCs do not bypass the lungs in two mouse
models of renal injury, and is in agreement with our previous
data using healthy animals [25]. Thus, any positive effects
on tissue regeneration and/or repair seen after IV adminis-
tration of MSCs are likely related to mechanisms that do not
involve the cells migrating and integrating with the renal
tissue. Further, this study reinforces the utility of combining
multiple reporter gene systems to individually track the
dynamics of cell distribution and persistence in different
organs not only in vivo but also postmortem in excised
tissues.
Conclusions
By applying an imaging strategy combining BLI and MRI,
we have been able to determine that the delivery of cell
therapies to the kidneys is dependent on cell type and route
of administration in murine models of renal injury. MSCs do
not home to the kidneys and are unable to bypass the lungs
when administered intravenously. Macrophages, on the other
hand, have a capacity to home and accumulate preferentially in
the injured kidneys, whether they are administered via the
venous or arterial circulation.Multiplex BLI enabled us to track
the biodistribution and persistence of each of these different
cell types individually in the same animal, revealing that their
fate is independent of one another.
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